Sacco, S., Ricci, S., Degan, D., & Carolei, A. (2012). Migraine in women: the role of hormones and their impact on vascular diseases. The journal of headache and pain, 13(3), 177-89. https://doi.org/10.1007/s10194-012-0424-y
Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. The journal of headache and pain. 2012;13(3):177-89. doi:10.1007/s10194-012-0424-y
Sacco, Simona, et al. "Migraine in women: the role of hormones and their impact on vascular diseases." The journal of headache and pain, vol. 13, no. 3, 2012, pp. 177-89.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Open Access
Free full text on PubMed Central (PMC3311830)
RRM Academy Synopsis
Migraine attacks track estrogen changes, and aura carries stroke risk
A 2012 review of studies in women reports that migraine attacks are linked to estrogen changes during the cycle, pregnancy and menopause. It also reports that migraine with aura is a stroke risk factor, and combined oral contraceptives may add to it.
Key Findings
Women had a 1-year migraine prevalence of 17% against 6% in men, and a lifetime incidence of 43% against 18%.
Migraine without aura peaks across 5 days: the 2 days before menstruation begins and the first 3 days of bleeding.
The association between migraine with aura and ischemic stroke was confirmed by three meta-analyses; no definite association was found for migraine without aura.
A meta-analysis of 9 studies found a pooled relative risk of ischemic stroke of 3.6 in women younger than 45 with any migraine, and 7.2 in current users of combined oral contraceptives.
The reported odds ratio for ischemic stroke was 34 among women with migraine who use oral contraceptives and smoke.
Interpretation
The article reviews cohort studies, case-control studies and meta-analyses published by 2012. Across them, migraine attacks cluster around the fall in estrogen before and during menstruation. Migraine with aura is linked with a higher risk of ischemic stroke. Among women younger than 45 with migraine of any type, that risk rises further with combined oral contraceptive use and smoking. The authors note that no studies had enough power to examine stroke risk by contraceptive use and migraine type together.
RRM Context
The review links migraine timing to estrogen change, which makes the ovulatory cycle relevant to when attacks occur. Charting attacks against cycle days records that timing. Suppressive medications such as combined oral contraceptives replace the cycle's hormones with a pill schedule. The review reports that among users whose migraine persists, attacks are more likely in the pill-free week. Restorative reproductive medicine seeks the cause of a cycle-linked pattern before prescribing.
Our editorial summary of this paper, not the article's abstract.
Abstract
Migraine is a predominantly female disorder. Menarche, menstruation, pregnancy, and menopause, and also the use of hormonal contraceptives and hormone replacement treatment may influence migraine occurrence. Migraine usually starts after menarche, occurs more frequently in the days just before or during menstruation, and ameliorates during pregnancy and menopause. Those variations are mediated by fluctuation of estrogen levels through their influence on cellular excitability or cerebral vasculature. Moreover, administration of exogenous hormones may cause worsening of migraine as may expose migrainous women to an increased risk of vascular disease. In fact, migraine with aura represents a risk factor for stroke, cardiac disease, and vascular mortality. Studies have shown that administration of combined oral contraceptives to migraineurs may further increase the risk for ischemic stroke. Consequently, in women suffering from migraine with aura caution should be deserved when prescribing combined oral contraceptives.